Full-Year Revenue Growth
Total revenue for FY2025 was $329.5M, up 12% year-over-year.
Strong Q4 Performance
Q4 revenue was $103.6M, up 21% year-over-year, driven by lymphedema (+16% to $89.5M) and airway clearance (+66% to $14.1M).
Expanded Gross Margin and Profitability
Full-year gross margin expanded 190 basis points to 75.9%; Q4 gross margin was 78.2% vs 75.2% in Q4 2024. Adjusted EBITDA increased 21% year-over-year to $44.8M (Q4 adjusted EBITDA $22.0M vs $16.2M prior-year).
Cash Generation and Balance Sheet Actions
Generated nearly $43M in operating cash flow for 2025; repaid $26.3M term loan, repurchased $26.5M of stock, and ended 2025 with $83.4M in cash and no outstanding borrowings.
Commercial Execution & Salesforce Buildout
Achieved year-end sales rep hiring goal, implemented a 1 account manager : 1 product specialist model, and reported improved sales productivity supported by CRM adoption.
Airway Clearance Momentum
AffloVest sales increased 66% year-over-year in Q4 and 6% sequentially; management believes they have a market-leading position in airway clearance.
Strategic Acquisition — LymphaTech
Announced acquisition of LymphaTech to add 3D digital scanning for fluid measurement and monitoring; commercialized product immediately expands product portfolio and supports TAM expansion toward undiagnosed patient population (~20M US symptomatic patients).
Clinical Evidence Progress
2-month RCT results for Flexitouch Plus published; 6-month manuscript submitted, strengthening clinical value and payer discussions for head & neck lymphedema.
Product Roadmap & Innovation
Introduced Nimbl and achieved leadership in basic compression pumps; submitted 510(k) for next-gen AffloVest and planning phased enhancements for Flexitouch (smaller, lighter, connectivity).
Operational Technology Investments
Rolled out CRM and completed phase one of AI platform for order intake and medical record review; expected to improve speed to therapy, reduce errors and enhance operating efficiency.